These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26706241)

  • 21. Drug discovery targeting cell division proteins, microtubules and FtsZ.
    Ojima I; Kumar K; Awasthi D; Vineberg JG
    Bioorg Med Chem; 2014 Sep; 22(18):5060-77. PubMed ID: 24680057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
    Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
    Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.
    Hood KA; West LM; Rouwé B; Northcote PT; Berridge MV; Wakefield SJ; Miller JH
    Cancer Res; 2002 Jun; 62(12):3356-60. PubMed ID: 12067973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously.
    Gapud EJ; Bai R; Ghosh AK; Hamel E
    Mol Pharmacol; 2004 Jul; 66(1):113-21. PubMed ID: 15213302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclostreptin and microtubules: is a low-affinity binding site required?
    Prussia AJ; Yang Y; Geballe MT; Snyder JP
    Chembiochem; 2010 Jan; 11(1):101-9. PubMed ID: 19946930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.
    Hamel E; Day BW; Miller JH; Jung MK; Northcote PT; Ghosh AK; Curran DP; Cushman M; Nicolaou KC; Paterson I; Sorensen EJ
    Mol Pharmacol; 2006 Nov; 70(5):1555-64. PubMed ID: 16887932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of microtubule targeting agents for cancer therapy.
    Karahalil B; Yardım-Akaydin S; Nacak Baytas S
    Arh Hig Rada Toksikol; 2019 Sep; 70(3):160-172. PubMed ID: 32597128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells.
    Das V; Miller JH
    Brain Res; 2012 Dec; 1489():121-32. PubMed ID: 23085090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments.
    Churchill CD; Klobukowski M; Tuszynski JA
    Chem Biol Drug Des; 2015 Aug; 86(2):190-9. PubMed ID: 25376845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents.
    Altmann KH; Gertsch J
    Nat Prod Rep; 2007 Apr; 24(2):327-57. PubMed ID: 17390000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin.
    Madiraju C; Edler MC; Hamel E; Raccor BS; Balachandran R; Zhu G; Giuliano KA; Vogt A; Shin Y; Fournier JH; Fukui Y; Brückner AM; Curran DP; Day BW
    Biochemistry; 2005 Nov; 44(45):15053-63. PubMed ID: 16274252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular recognition of peloruside A by microtubules. The C24 primary alcohol is essential for biological activity.
    Pera B; Razzak M; Trigili C; Pineda O; Canales A; Buey RM; Jiménez-Barbero J; Northcote PT; Paterson I; Barasoain I; Díaz JF
    Chembiochem; 2010 Aug; 11(12):1669-78. PubMed ID: 20665616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of tumor hypoxia in acquisition of resistance to microtubule-stabilizing drugs.
    Das V; Štěpánková J; Hajdúch M; Miller JH
    Biochim Biophys Acta; 2015 Apr; 1855(2):172-82. PubMed ID: 25662312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Microtubule Stabilization by Epothilone B Depend on the Type and Age of Neurons.
    Jang EH; Sim A; Im SK; Hur EM
    Neural Plast; 2016; 2016():5056418. PubMed ID: 27872763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of natural product microtubule stabilizers on microtubule assembly: single agent and combination studies with taxol, epothilone B, and discodermolide.
    Gertsch J; Meier S; Müller M; Altmann KH
    Chembiochem; 2009 Jan; 10(1):166-75. PubMed ID: 19058273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microtubule-associated proteins as targets in cancer chemotherapy.
    Bhat KM; Setaluri V
    Clin Cancer Res; 2007 May; 13(10):2849-54. PubMed ID: 17504982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site.
    Edler MC; Buey RM; Gussio R; Marcus AI; Vanderwal CD; Sorensen EJ; Díaz JF; Giannakakou P; Hamel E
    Biochemistry; 2005 Aug; 44(34):11525-38. PubMed ID: 16114889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.